UK and Singapore strengthen health innovation ties with new regulatory agreement

By:  Nana Appiah Acquaye

The Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore’s Health Sciences Authority have signed an updated Memorandum of Understanding aimed at deepening collaboration in health innovation and regulatory practices.

The agreement, signed in London, builds on an existing partnership first established in 2008 and introduces expanded cooperation across key areas including clinical trials, pharmaceutical manufacturing, and medical devices.

Officials from both agencies said the revised framework will enhance information sharing and enable the exchange of technical expertise in advanced areas of modern healthcare, supporting the development and regulation of innovative medical products.

The collaboration also forms part of broader joint efforts under the Access Consortium, a global initiative that promotes regulatory alignment and cooperation among leading health authorities.

As part of the strengthened partnership, both sides will advance the Regulatory Innovation Corridor, an initiative designed to streamline engagement between companies and regulators. The corridor is expected to help developers design more robust clinical studies, reduce regulatory delays, and accelerate the delivery of safe and effective healthcare innovations to patients.

The signing ceremony was attended by senior officials from both organisations, reflecting a shared commitment to strengthening international cooperation in healthcare regulation and innovation.